Blog

Materials for the Administration of Human Genetic Resources

Release Date:

2023-03-30 16:57

I. Approval for the Collection of Human Genetic Resources in China

WeChat Image_20230420105601.jpg

 

Application Form Template Download:

https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Collection_of_Audits.zip

 

II. Approval for the Preservation of China’s Human Genetic Resources

2.jpg

 

Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Quality Assurance Template.doc

III. Approval for International Collaborative Scientific Research Involving China’s Human Genetic Resources

3.jpg

Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/National_Collaborative_Science_and_Technology_Research_Accreditation.zip

 

IV. Approval for the Export of China’s Human Genetic Resources

4.jpg

 

Application Form Template Download:

https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Materials_Review.zip

 

V. Filing of International Collaborative Clinical Trials Involving China’s Human Genetic Resources

5.png

 

Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/National Joint Testing Project Template.doc

VI. Filing for the External Provision or Open Access to Information on China’s Human Genetic Resources

6.png

 

Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Information_Sheets_and_Folders.zip

 

VII. List of Materials to Be Submitted via the Online Filing System

1 Application Form (Attachment)

2. The business license or organizational code certificate, and the legal person certificate of this entity

3. Supporting documentation specifying the Chinese-side and foreign-side institutions

Application Form Template Download:

https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/ktwssbxttjclqd.docx

 

 

Previous page

Major Positive News: CDE Issues for Public Comment the “Procedures for Accelerating the Review and Approval of Marketing Applications for Innovative Drugs (Trial)”!

Shenzhen Introduces the Nation’s First Special Legislation on the Cell and Gene Industry

Next page

Related News

HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)

Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.

HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)

The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.

(3) Batch Stability and Performance Verification | Upholding Quality, Striving for Progress While Maintaining Stability

This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.

(II) Security Assurance Section | Safety First, Defense Prioritized

Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.

(1) Compliance and Traceability Section | Establishing a Foundation of Compliance, Ensuring Source Tracing

This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.

Compliance as the Foundation, Safety as the Core | The Steadfast Commitment and Confidence Behind Heyou Sheng’s Serum Substitute

In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.